ELITE PHARMACEUTICALS INC /NV/ Quarterly Weighted Average Number of Shares Outstanding, Basic from Q3 2010 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly/annual Weighted Average Number of Shares Outstanding, Basic history and growth rate from Q3 2010 to Q3 2024.
  • Elite Pharmaceuticals Inc /Nv/ Weighted Average Number of Shares Outstanding, Basic for the quarter ending September 30, 2024 was 1.07B shares, a 5.36% increase year-over-year.
  • Elite Pharmaceuticals Inc /Nv/ annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 1.02B shares, a 0.25% increase from 2022.
  • Elite Pharmaceuticals Inc /Nv/ annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 1.01B shares, a 0.23% increase from 2021.
  • Elite Pharmaceuticals Inc /Nv/ annual Weighted Average Number of Shares Outstanding, Basic for 2021 was 1.01B shares, a 7.17% increase from 2020.
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 1.07B +54.4M +5.36% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 1.07B +54.4M +5.36% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 1.02B +2.53M +0.25% Jan 1, 2024 Mar 31, 2024 10-K 2024-07-01
Q4 2023 1.01B +853K +0.08% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-14
Q3 2023 1.01B +1.69M +0.17% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 1.01B +2.53M +0.25% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 1.01B +2.3M +0.23% Jan 1, 2023 Mar 31, 2023 10-K 2024-07-01
Q4 2022 1.01B +2.63M +0.26% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-14
Q3 2022 1.01B +946K +0.09% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 1.01B +2.18M +0.22% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 1.01B +67.6M +7.17% Jan 1, 2022 Mar 31, 2022 10-K 2023-06-29
Q4 2021 1.01B +2.11M +0.21% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-14
Q3 2021 1.01B +97.7M +10.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 1.01B +169M +20.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 943M +111M +13.3% Jan 1, 2021 Mar 31, 2021 10-K 2022-06-29
Q4 2020 1.01B +180M +21.7% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q3 2020 914M +84.2M +10.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 841M +13M +1.57% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 832M +18.2M +2.23% Jan 1, 2020 Mar 31, 2020 10-K 2021-06-14
Q4 2019 829M +9.98M +1.22% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-16
Q3 2019 829M +17.1M +2.11% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 828M +24.5M +3.05% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 814M +18.1M +2.27% Jan 1, 2019 Mar 31, 2019 10-K 2020-06-30
Q4 2018 819M +31M +3.93% Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-10
Q3 2018 812M +29.8M +3.81% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 803M -16.3M -1.99% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 796M -42.6M -5.08% Jan 1, 2018 Mar 31, 2018 10-K 2019-06-21
Q4 2017 788M -116M -12.9% Oct 1, 2017 Dec 31, 2017 10-Q 2019-02-11
Q3 2017 782M -24.4M -3.03% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 819M +96.5M +13.4% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 839M +165M +24.4% Jan 1, 2017 Mar 31, 2017 10-K 2018-06-14
Q4 2016 905M +220M +32.1% Oct 1, 2016 Dec 31, 2016 10-Q 2018-02-09
Q3 2016 807M +142M +21.3% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 723M +75.9M +11.7% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 674M +82.7M +14% Jan 1, 2016 Mar 31, 2016 10-K 2018-06-14
Q4 2015 685M +83.7M +13.9% Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-09
Q3 2015 665M +87.6M +15.2% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-09
Q2 2015 647M +81.7M +14.5% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 591M +128M +27.7% Jan 1, 2015 Mar 31, 2015 10-K 2017-06-14
Q4 2014 601M +92.5M +18.2% Oct 1, 2014 Dec 31, 2014 10-Q 2016-02-09
Q3 2014 578M +156M +36.9% Jul 1, 2014 Sep 30, 2014 10-Q/A 2015-12-30
Q2 2014 565M +177M +45.7% Apr 1, 2014 Jun 30, 2014 10-Q/A 2015-12-30
Q1 2014 463M +114M +32.6% Jan 1, 2014 Mar 31, 2014 10-K 2016-06-15
Q4 2013 509M +158M +45.2% Oct 1, 2013 Dec 31, 2013 10-Q 2015-02-17
Q3 2013 422M +73.7M +21.2% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-14
Q2 2013 388M +50.7M +15% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-14
Q1 2013 349M +89.9M +34.7% Jan 1, 2013 Mar 31, 2013 10-K 2014-06-30
Q4 2012 350M +88.2M +33.6% Oct 1, 2012 Dec 31, 2012 10-Q 2014-02-14
Q3 2012 348M +100M +40.3% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-14
Q2 2012 337M +105M +45.4% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-14
Q1 2012 259M Jan 1, 2012 Mar 31, 2012 10-K 2013-06-21
Q4 2011 262M -96.6B -99.7% Oct 1, 2011 Dec 31, 2011 10-Q 2013-02-14
Q3 2011 248M +156M +169% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-14
Q2 2011 232M Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-14
Q4 2010 96.9B Oct 1, 2010 Dec 31, 2010 10-Q 2012-02-14
Q3 2010 92.4M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.